Name change to connect Orphazyme buyer Kempharm with rare disease area
The company that bought embattled biotech company Orphazyme’s main asset in 2022 is now rebranding to align itself closer with its mission to treat rare diseases.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
US-based Kempharm, which in 2022 acquired a Niemann-Pick type C treatment candidate, the main asset of embattled biotech company Orphazyme, is changing names.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Former US head of Leo Pharma gets board seat at Kempharm
For subscribers
Orphazyme is now officially in American hands
For subscribers
.jpg&w=384&q=75)
